Lactoferrin Versus Ferrous Fumarate for Treatment of Mild to Moderate Iron Deficiency Anemia During Pregnancy
Study Details
Study Description
Brief Summary
This study will conducted to evaluate and comparison between the effectiveness, safety and acceptability of lactoferrin alone, ferrous fumarate alone and combination of both for the treatment of mild to moderate IDA during pregnancy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
Anemia in pregnancy is a major public health problem, where it has been estimated that 41.8% of pregnant women worldwide are anemic .
Iron deficiency anemia (IDA) is the condition in which there is anemia due to a lack of iron. IDA develops when available iron is insufficient to support normal red cell production and is the most common type of anemia Anemia has a significant impact on the health of the fetus as well as that of the mother. It impairs the oxygen delivery through the placenta to the fetus and interferes with the normal intrauterine growth, leading to fetal loss and perinatal deaths. Anemia is associated with increased preterm labor (28.2%), preeclampsia (31.2%), and maternal sepsis.
The daily requirement of iron is around 1.5 mg in nonpregnant women. This requirement increases dramatically during pregnancy to reach 6-7 mg/day (total 1000 mg) with advanced gestational age. Pregnancy causes a twofold to threefold increase in the requirement for iron and a 10- to 20-fold increase in folate requirement. The increase in demand for iron is mainly due to fetal requirement, placenta, blood volume, tissue accretion, and the intra-partum potential for blood loss
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Oral lactoferrin women who take oral lactoferrin sachets 100 mg twice daily for one month. |
Drug: Lactoferrin and ferrous fumarate
Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .
Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .
Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily .
Other Names:
|
| Active Comparator: Oral ferrous fumarate women who take oral ferrous fumarate tablet 30 mg elemental iron twice daily for one month. |
Drug: Lactoferrin and ferrous fumarate
Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .
Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .
Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily .
Other Names:
|
| Active Comparator: Combined lactoferrin & ferrous fumarate women who take lactoferrin sachets 100 mg and ferrous fumarate tablet 30 mg elemental iron once daily for one month. |
Drug: Lactoferrin and ferrous fumarate
Group 1:include 50 women will receive oral lactoferrin 100mg twice daily .
Group 2: include 50 women will receive oral Ferrous fumarate 30mg elemental iron twice daily .
Group 3: include 50 women will receive oral combined lactoferrin 200mg and ferrous fumarate 60mg elemental iron once daily .
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Increase in blood hemoglobin. [one month]
mean difference in hemoglobin level between pre treatment and post treatment.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Pregnant women from 24-36 weeks of gestation.
-
Mild to moderate anemia.
Exclusion Criteria:
-
Women with a history of anemia due to any other causes other than IDA.
-
Severe anemia requiring blood transfusion.
-
History of peptic ulcer.
-
known hypersensitivity to iron preparations.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- u1111-1210-1436